Dados do Trabalho

Título

IDIOPATHIC POLYPOIDAL VASCULOPATHY

Resumo

To show the efficacy of laser photocoagulation associated with intravitreal antiangiogenic in cases of idiopathic polypoidal asculopathy.
Patient AAP, male, 54 years old, nursing assistant, complaining of low visual acuity in the right eye. Ophthalmoscopy showed a
macular edematous halo, microhemorrhages and chronicircinate serous lipid exudation between the macula and the superior temporal vascular arcade; in the left eye hypochromic paramacular areas. Fluorescein angiography showed hyperfluorescence from a vascular lesion between the macula and the superior temporal arcade, already visible in the choroidal phase (abnormality in the internal vessels of the choroid, consisting of a dilated network and multiple aneurysmal terminal protuberances with a polypoidal configuration), which rogressed with the course of the examination (leakage) and culminated with staining in the late phase.
We opted for watchful waiting until a greater absorption of serosanguinous detachments was achieved. Then, laser photocoagulation and intravitreal antiangiogenic therapy were performed. Final visual acuity was 20/25 in the right eye.
There was an extensive pooling area inferiorly and temporally to the macula, with areas of hypofluorescence due to hemorrhagic
blockage (serosanguineous detachment of the pigment epithelium); other areas of blockade hypofluorescence due to
punctiform hemorrhages. We observed less intense hyperfluorescence delimiting the sensory detachment area. In the left eye, areas of hyperfluorescence due to defects in the paramacular pigment epithelium. The diagnostic hypothesis was idiopathic polypoidal choroidal vasculopathy in the right eye.
The administration of intravitreal antiangiogenic combined with laser photocoagulation proved to be effective as a treatment for
cases of idiopathic polypoidal vasculopathy, with good recovery and maintenance of visual acuity.

Referências Bibliográficas

REFERÊNCIAS BIBLIOGRÁFICAS
[1] L. J. Hernandez-Pastor, A. Ortega, A. Garcia-Layana, and J.
Giraldez, “Ranibizumab for neovascular age-related macular
degeneration,” American Journal of Health-System Pharmacy,
vol. 65, no. 19, pp. 1805–1814, 2008.
[2] B. Morris, F. Imrie, A. M. Armbrecht, and B. Dhillon, “Agerelated
macular degeneration and recent developments: new hope for old
eyes?” Postgraduate Medical Journal, vol. 83, no.979, pp. 301–
307, 2007.
[3] P. Mitchell, J. F. Korobelnik, P. Lanzetta et al., “Ranibizumab
(Lucentis) in neovascular age-related macular degeneration:
evidence from clinical trials,” British Journal of Ophthalmology,
vol. 94, no. 1, pp. 2–13, 2010.
[4] A. E. Fung, G. A. Lalwani, P. J. Rosenfeld et al., “An optical
coherence tomography-guided, variable dosing regimen
with intravitreal ranibizumab (Lucentis) for neovascular age related
macular degeneration,” American Journal of Ophthalmology, vol.
143, no. 4, pp. 566–583.e2, 2007.